Full Title: Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
FREE BONUS REPORT(S): When you buy below report, you may pick 3 additional cancer reports for free from this list
(Value: 7,400 USD)
Introduction Despite the plethora of once-daily drugs available for the treatment of ADHD, physicians consistently prescribe immediate release formulations. To bolster revenues, manufacturers must continue to promote awareness of ADHD at all levels, but most also seek to further differentiate their once-daily products from generics and other branded products in the eyes of both the patient and the physician. Scope - Analysis is based on a survey of 180 prescribing physicians in the seven major markets as well as in-depth interviews with ADHD Key Opinion Leaders
- Detailed treatment trees showing the prevalence, diagnosis and treatment rates of ADHD across the seven major markets
- Analyzes the first and second-line treatment of children and adolescents with ADHD
- Identifies diagnostic and therapeutic unmet needs, highlights how manufacturers can drive patient identification as well as bolster drug prescriptions
Highlights Datamonitor primary research has identified variances in class- and brand-prescribing preferences among physicians, although prescribing trends generally follow recognized national and international guidelines. However, there is concern over the use of combination therapies in the absence of conclusive clinical trial data. Only 12.3% of patients are diagnosed, indicating that a huge proportion of patients remain undiagnosed and untreated. Although the awareness of ADHD is ever growing, there are still significant gaps between, knowledge, recognition and referral of the disease. Datamonitor has highlighted these and provides counteractive strategic recommendations. Only 20% of patients receive longer-acting, once-daily drugs at first-line, falling to 3% at second-line, with physicians preferring immediate-release formulations. Consequently, Datamonitor has identified numerous lifecycle strategies to bolster long-acting drug sales. Reasons to Purchase - Identify commercial opportunities by benchmarking current products and assessing unmet needs and future market potential
- Assess the size of the drug-treated population through an understanding of the prevalence of ADHD with comorbid psychiatric and behavioral disorders
- Communicate with physicians more effectively, through an understanding of prescribing behavior
Pages: 241 Table of Contents Download TOC in PDF
Stakeholder Insight Reports View all available Stakeholder Insight Reports
|
